NK cells have shown promise in therapy of hematological cancers, in particular against acute myeloid leukemia. In contrast, the more NK cell-resistant acute lymphoblastic leukemia (ALL) is difficult to treat with NK-cell based therapies, and we hypothesized that preactivation of NK cells could overcome this resistance. We show in pediatric and adult patients with T-cell ALL (T-ALL) perturbed NK cell effector functions at diagnosis. Using an in vivo rat model for T-ALL, Roser leukemia (RL), suppressed NK cell effector functions was observed. NK cells from T-ALL patients had reduced expression of the activating receptors NKp46 and DNAM-1, but not NKG2D. In contrast to T-ALL patients, NKG2D but not NKp46 was down-regulated on NK cells during rat RL. Decreased frequencies of terminally differentiated NKG2A + CD57 -CD56 dim NK cells in human T-ALL was paralleled in the rat by reduced frequencies of bone marrow NK cells expressing the maturation marker CD11b, possibly indicating impairment of differentiation during leukemia. RL was highly resistant to autologous NK cells, but this resistance was overcome upon pre-activation of NK cells with IL-12, IL-15, and IL-18, with concomitant up-regulation of activation markers and activating receptors. Importantly, adoptive transfers of IL-12, IL-15, and IL-18 pre-activated NK cells significantly slowed progression of RL in vivo. The data thus shows that T-ALL blasts normally resistant to NK cells may be targeted by cytokine pre-activated autologous NK cells, and this approach could have potential implications for immunotherapeutic protocols using NK cells to more efficiently target leukemia.
Introduction
NK cells are increasingly attractive for immunotherapies towards cancers. [1] [2] [3] NK cell effector functions are induced when signals from one or more activating receptors override inhibition through inhibitory receptors binding to MHC class I. 4 Ligands for activating NK cell receptors, such as NKG2D, DNAX Accessory Molecule-1 (DNAM-1), and the natural cytotoxicity receptors (NCRs) NKp46 and NKp30 are variably up-regulated on malignant cells, rendering them susceptible to NK cells. 5 NK cells have been successfully used in the treatment of haematological cancers. In particular, haploidentical KIR-mismatched bone marrow transplantations, 6 or infusions of haploidentical KIR-ligand mismatched NK cells promoted eradication of leukemic blasts in acute myeloid leukemia (AML) patients. 7 In contrast, there has been limited success in similar treatments of adult acute lymphoblastic leukemia (ALL) patients, while some success with paediatric patients is reported. 8 ALL blasts are generally resistant to NK cells, as they less frequently express ligands for activating NK cell receptors, in combination with normal MHC class I expression levels. 9, 10 Reduced surface levels of DNAM-1, NKp46, NKp30, and/or NKG2D by NK cells are frequently observed in AML and variably in ALL patients. 9, [11] [12] [13] [14] . Low surface expression of activating receptors at diagnosis is correlated to low NK cell activity, poor outcome, and increased risk of relapse. [15] [16] [17] [18] [19] Reduced NK cell activity is also reported in patients with other haematological disorders, such as chronic myeloid leukemia (CML) and myelodysplastic syndrome (MDS). 20, 21 Reduced NKG2D expression is mediated by both TGF-β as well as soluble NKG2D ligands released from blasts, [22] [23] [24] but whether NKG2D is directly involved in targeting leukemic blasts is controversial. 25 In contrast, reduced expression of DNAM-1 has been directly correlated to inefficient NK cell-mediated killing of malignant cells. [26] [27] [28] Pre-activation of NK cells with cytokines prior to infusion has been attempted to enhance tumor clearance. While use of the classical NK-activating cytokine IL-2 alone has shown limited success, 29 combinatorial pre-activation of NK cells with IL-12, IL-15, and IL-18 has been shown to result in significant tumor regression in a mouse model of lymphoma, 30 suppression of graft-versus-host disease in the mouse, 31 and, importantly, in a clinical trial of refractory AML. 32 Short-term pre-activation of human or mouse NK cells with IL-12, IL-15, and IL-18 has been shown to result in generation of NK cells with superior effector functions as compared to activation with IL-2 or IL-15 alone. 33 Re-stimulation of these cytokineactivated NK cells leads to enhanced functional activity; hence NK cells differentiated after IL-12, IL-15, and IL-18 pre-activation was termed cytokine-induced memory-like cells. [33] [34] [35] [36] Their potential utility in immunotherapy is thus obvious.
T-cell ALL (T-ALL) results from a malignancy of T-cell progenitors, representing 15
% of paediatric and 25 % of adult acute leukemia cases. Significant improvement in intensive risk-adapted chemotherapy protocols have yielded more than 80 % 5-year overall survival for paediatric T-ALL patients. Compared to B-cell derived acute leukemia (B-ALL), both paediatric and adult T-ALL patients remain at increased risk for induction failure and relapse. 37, 38 Most studies investigating NK cell recognition of ALL have focussed on B-ALL, while studies on NK cells and T-ALL are fragmentary. Here, we have addressed the interplay between NK cells and T-ALL, by phenotypic and functional characterization of NK cells in T-ALL patients at diagnosis, and complemented with a rat model for T-ALL, Roser leukemia (RL), to study NK-cell mediated targeting of T-ALL. RL is a radiation-induced leukemia from the PVG rat strain, with similar pathology to human T-ALL. 39 RL primarily infiltrates the spleen upon i.v. injection, but affects several organs at late stages such as the bone marrow, liver, lungs, thymus, testis, and meninges.
We show suppressed NK cell functions during acute T-ALL disease, both in human and in the rat, and show in the rat model that suppressed NK cell functions are extrinsic to the blasts, indicative of suppression mediated by other factors or cells in the environment. Pre-activation of autologous NK cells with IL-15, IL-12, and IL-18 sensitized NK cells to the otherwise highly resistant RL blasts, and upon adoptive transfer in vivo, pre-activated NK cells resulted in significant reductions in RL load. This implies that pre-activation of NK cells is of potential immunotherapeutic use against otherwise resistant T-ALL.
Results

Deficient NK cell functions and down-regulated expression of DNAM-1 and NKp46 in T-ALL patients
NK cell effector functions were tested in PBMC obtained at diagnosis from 3 pediatric T-ALL patients recruited in the period 2014-2016 at Oslo University Hospital, with PBMC from age-matched healthy children as controls. PBMC from another 10 pediatric and 9 adult T-ALL patients recruited at time of diagnosis in the period 1982-1997 were obtained from the Royal Victoria Infirmary in Newcastle, UK. NK cell numbers in these samples were too low for functional analysis. Low degranulation, as assessed by surface deposition of the granule marker CD107a, and low IFN-γ production in response to the NK cell sensitive tumor target K562 was observed in CD3 -CD56 dim NK cells from pediatric T-ALL patients ( Fig. 1A and B ).
We also observed a reduction in the proportion of CD56 dim NK cells expressing CD8 in both adult and pediatric patients (Fig. 1C ). CD8 + NK cells are suggested to represent more functionally active NK cells in terms of both cytotoxicity and cytokine production. 40, 41 Next, expression of activating and inhibitory NK cell receptors by CD3 -CD56 dim NK cells in pediatric and adult T-ALL patients was compared to healthy children or adults.
Reduced frequencies of NKp46 + NK cells were observed in the pediatric group, and of DNAM-1 + NK cells in both patient groups compared to healthy controls ( Fig. 2A ). NKp46 expression levels were reduced in both adult and pediatric patients, while DNAM-1 expression levels were reduced in the pediatric patient group only ( Fig. 2B ). Frequencies and expression levels of NKG2D in NK cells were similar between patients and controls ( Fig. 2A and B). NK cells expressing the inhibitory receptors NKG2A and NKR-P1A were present at similar frequencies in patients and controls, but NKR-P1A was expressed at higher levels by NK cells from pediatric patients ( Fig. 2A and B ).
NK cell receptor repertoires are skewed during T-ALL in the rat
A rat model of T-ALL was utilized to investigate underlying mechanisms of how T-ALL affects NK cells. The leukemia, RL, was injected i.v. and animals sacrificed when blasts reached >30 % of PBMC. At this point, the spleen was grossly enlarged. The numbers of NK cells was comparable in blood and spleen in RL and healthy rats (Suppl. Fig 1A) , but a skewing of NK cell subsets was observed during RL. In the rat, three major NK cell subsets are found. Two of the subsets are mature and fully functional, and express either Ly49s3 or the inhibitory NKR-P1B receptor, 42 while a third terminally differentiated NKR-P1B bright subset is found in the blood and gut. 43 Higher frequencies of NKR-P1B dim NK cells were found in both blood and bone marrow in rats with RL, accompanied by reduced proportions of NKR-P1B bright cells in the blood (Fig. 3A ). The same pattern was observed for total numbers of each subset, though not to statistical significance (Suppl. Fig. 1B -C). This skewing was not caused by preferential proliferation of NKR-P1B dim NK cells (Suppl. Fig.   1D ), suggesting differentiation could be affected. In the mouse, CD11b and CD27 distinguish immature and mature NK cells. This is not as clear in the rat, 43 but a skewing towards more CD27 + and fewer CD11b + NKR-P1B dim cells was observed in the bone marrow (Suppl. Fig.   1E ). Human NK cells differentiate from CD56 bright to CD56 dim NK cells, and further along a pathway with increasing CD57 and decreasing NKG2A frequencies. 44, 45 A tendency for lower frequencies of CD57 + NKG2A -NK cells was found in pediatric T-ALL patients (p=0.085), with a similar trend for adult T-ALL patients (Suppl. Fig. 1F ), indicating that, as in the rat, NK cell differentiation could be affected.
Reduced NK cell functions and skewing of NK cell receptor repertoire in rats with T-ALL.
Similarly to human patients, NK cells from rats with RL showed low degranulation against an NK cell sensitive tumor target ( Fig. 3B ), and reduced production of IFN-γ in response to stimulation of activating receptors NKp46, Ly49s3, or NKR-P1A, or in response to IL-12 or IL-18 in combination with IL-2 ( Fig In contrast to human patients, NKG2D expression was lower in NK cells from spleen, blood, and bone marrow from rats with RL ( Fig. 3E ), accompanied by reduced frequencies in in the spleen (Suppl. Fig. 2A ). Expression levels and frequencies of NKp46 + , Ly49s3 + , or NKR-P1A + NK cells were similar in healthy and RL rats ( Fig. 3F , Suppl. Fig. 2B , and data not shown). Lack of antibodies towards rat DNAM-1 prevented testing its surface expression.
Dnam1 was similarly expressed in NK cells purified from RL or healthy rats, but this was also observed for Nkg2d, indicating post-transcriptional regulation (Suppl. Fig. 2C ). Further analysis of RL indicated limited expression of the NKG2D ligands Rae1l or Rrlt, while these were expressed by the NK sensitive rat tumor cell line YB2/0 ( Fig. 3G ). RL expressed Pvr (CD155), a ligand for DNAM-1, at higher levels than primary T cells ( Fig. 3G ).
Reduced NK cell functionality and down-modulation of NKG2D in the rat was not directly mediated by the RL blasts. In vitro overnight co-cultures of enriched, autologous splenic NK cells from healthy rats with RL did not affect either degranulation towards YAC-1 or IFN-γ production in response to IL-12 (Suppl. Fig. 3A and B), nor NKG2D surface expression upon overnight co-culture of enriched NK cells with RL (Suppl. Fig. 3C ).
Moreover, serum concentrations of TGF-β was similar in healthy and sick rats (Suppl. Fig.   3D ), and although RL expressed Tgfb at higher levels than primary T cells (Suppl. Fig. 3E ), we did not detect elevated TGF-β levels in in vitro cultures of RL alone or with enriched NK cells (Suppl. Fig. 3F ). Moreover, overnight or 5-day cultures of NK cells with serum from rats with RL did not affect IFN-γ production or NKG2D expression levels (Suppl. Fig. 3G and H, and data not shown). This indicates that soluble serum factors are unlikely to directly affect NK cells, although exogenous TGF-β reduced NKG2D expression in vitro (Suppl. Fig. 3I ).
NK cells pre-activated with IL-15, IL-12, and IL-18 potently kill the resistant RL blasts.
RL are resistant to lysis by autologous, IL-2 activated NK cells. 46 Here, poor degranulation and low cytotoxicity by resting, autologous NK cells in response to RL is shown ( Fig. 4A and B ). Extending the killing assay from 4 to 20 hrs led to increased specific lysis of RL independent of Fas/Fas-L ( Fig. 4B ). Also conjugate formation between NK cells and RL increased over time (Suppl. Fig. 4A ). Compared to primary T cells, expression of Trailr2, Fas, and adhesion molecules CD2, CD48, and ICAM-1 was low on RL, while MHC class I was similarly expressed, indicating reduced potential for interaction of NK cells with RL (Suppl. Fig. 4B and C).
IL-15 in combination with IL-12 and IL-18 is shown to enhance NK cell effector functions and tumor recognition. 30, 32 We therefore tested targeting of RL by autologous, enriched NK cells from healthy rats pre-treated with either IL-15 alone or in combination with IL-12 and IL-18. Heightened activity of NK cells was observed with increased expression of CD25 and CD69, in particular after culture with all three cytokines ( Fig. 4D and data not shown). Moreover, increased expression levels of NKG2D, Ly49s3, and FasL, but not NKp46, was observed after pre-activation with IL-15 alone or with IL-12 and IL-18 ( Fig.   4D ). qRT-PCR analysis showed up-regulation of Dnam1 (Fig. 4C ). IL-15 pre-activated NK cells demonstrated higher cytolytic activity towards the resistant RL compared to untreated NK cells, which was further enhanced by IL-12, IL-15, and IL-18 pre-activation reaching levels comparable to killing of the sensitive YB2/0 targets by untreated NK cells ( Fig. 4D ).
While lysis of YB2/0 targets was partially reduced by NKG2D antibody blockade, lysis of RL appeared to be independent of NKG2D. This correlate with the expression of NKG2D ligands by YB2/0 but not by RL (Fig. 3G ), and suggests that killing of RL by cytokine pre-activated NK cells is mediated by other activating receptor(s), possibly via DNAM-1/CD155.
IL-15/12/18 pre-activated NK cells slow RL development in vivo.
To test whether IL-12, IL-15, and IL-18 pre-activated NK cells target RL also in vivo, we established a model where rats were initially sub-lethally irradiated at 4 Gy to facilitate engraftment of transferred NK cells. Also, irradiation was previously shown to be necessary for effective tumor clearance by cytokine pre-activated NK cells in the mouse. 30 RL was injected 24 hrs post irradiation, followed by adoptive transfer of 4-6 x 10 6 IL-12, IL-15, and IL-18 pre-activated CD45.1 + NK cells at days 3, 6, and 9. Control rats were irradiated and injected with RL only. All rats were euthanized after 3-4 weeks when blast numbers exceeded 30 % of PBMC of control rats. A striking reduction in spleen weight ( Fig. 5A ), total numbers of RL in spleen and blood was observed in rats infused with pre-activated NK cells (Fig. 5B ).
The reduction of RL load was most striking in the blood (Fig. 5C ). Donor NK cells were clearly detectable in blood, spleen, and BM at sacrifice ( Fig. 5D and E). Although donor NK cells were pre-activated prior to adoptive transfer, they showed similar proliferative activity to host NK cells (CD45.2 + ) at sacrifice ( Fig. 5F ). Also, CD25, FasL, and activating receptors NKG2D and Ly49s3 were similarly expressed between donor and host NK cells ( Fig. 5G and data not shown), indicating that the heightened activation status achieved after overnight preactivation with IL-12, IL-15, and IL-18 is lost after adoptive transfer. This loss occurs within days after transfer and independently of whether rats are injected with RL or not (data not shown). Interestingly, NKp46 was consistently expressed at higher levels by donor NK cells at sacrifice ( Fig. 5G ).
Discussion
Immunotherapy with different NK cell-based strategies is showing promise in the clinic, in particular against AML. 6, 7, 32 Similar treatment of ALL has been less successful, likely due to their higher resistance towards NK cells. 8 T-ALL blasts are particularly resistant to NK cells, but studies investigating NK cells in context of T-ALL are fragmentary. Here, we examined NK cell phenotypes and functions during T-ALL, and show that pre-activation of NK cells with IL-12, IL-15, and IL-18 lead to targeting of T-ALL both in vitro and in vivo.
We observed diminished NK cell effector functions in pediatric T-ALL patients and in rats suffering from RL. These results are in line with previous studies reporting defective NK cell functions in patients with other haematological cancers, 15, 16, 28 which has been correlated to decreased expression levels of activating NK cell receptors, 14, 28 and increased risk of relapse. 15, 16, 18 In the rat model, serum or RL blasts does not affect NK cell functionality, suggesting that factors in tissues or suppressor cells, such as myeloid-derived suppressor cells (MDSC) may be involved.
NK cells from pediatric T-ALL patients expressed reduced surface levels of DNAM-1
and NKp46 but not NKG2D. This is in contrast to data from B-ALL and AML patients where NKG2D is generally down-regulated, 14 as it is during rat T-ALL. The discrepancy between rat and human T-ALL with respect to NKG2D is not likely mediated by differential ligand expression, as neither RL nor human T-ALL express NKG2D ligands. 9 Instead, downregulation of NKG2D has been attributed to soluble NKG2D ligands or TGF-β in serum, but serum from RL rats had no effect on NKG2D expression. Possibly other cells that are expanded in context of cancers, such as MDSC, are involved. 47, 48 It is currently unclear how NKp46 is down-regulated in the human T-ALL patients. NKp46 down-regulation observed in AML patients is independent of TGF-β, 12 and AML blasts lack expression of NKp46 ligands. 49 Potentially, soluble ligands or ligands expressed by extracellular vesicles could mediate NKp46 down-regulation. In contrast, the DNAM-1 ligands CD155 and CD112 are frequently found expressed by malignant cells, and directly linked to receptor downregulation. 26, 27 DNAM-1 surface expression was not tested in the rat due to unavailability of antibodies, but as CD155 was detected at the mRNA level in RL we hypothesize that DNAM-1 may be regulated similarly in human and rat T-ALL. We have also observed variable expression of CD155 and CD112 by human T-ALL blasts (unpublished observations). While this points to potential involvement of DNAM-1 in recognition of T-ALL, CD155 also interacts with the inhibitory receptor TIGIT expressed by human and rat NK cells.
The inhibitory NKR-P1A receptor was expressed at higher levels in the pediatric T-ALL patient group. In parallel, increased frequencies NK cells expressing the inhibitory NKR-P1B receptor were observed in rats with RL. The implication of enhanced expression of inhibitory NKR-P1s in unclear at the moment, as is the relationship between human NKR-P1A and the four NKR-P1 members in the rat; activating NKR-P1A and -F, and inhibitory NKR-P1B and -G. The ligand for human NKR-P1A, LLT1, or ligands for rat NKR-P1 receptors -the Clr molecules -are not expressed by T-cell leukemias. 50, 51 In rats with RL, NKR-P1B dim bone marrow NK cells contained more CD27 + CD11bcells than in healthy controls. While CD27 + CD11b -NK cells represent less differentiated cells in mice, CD27 and CD11b are not good maturation markers in the rat. However, bone marrow rat NK cells express less CD11b than peripheral NK cells, indicating that CD11b to a certain extent may predict maturation. 43 Also, in T-ALL patients, reduced frequencies of the most differentiated NK cells were observed. The human and rat data could suggest an impairment of NK cell differentiation, or alternatively, exhaustion of mature, effector NK cells.
We show that rat autologous NK cells poorly target T-ALL blasts. Previous studies have shown that pre-activating NK cells with combinations of IL-12, IL-15, and IL-18 upregulate activating NK cell receptors, enhance expression of the cytolytic molecules FasL, TRAIL, perforin, and granzyme B, 31 and induce a memory-like phenotype. 30, 33, 35, 36 Further, NK cells up-regulate CD25, rendering NK cells more sensitive to IL-2 driven activation 52 and expansion. 53 30, 32 Although there is a clear effect of infusing pre-activated NK cells, there is an obvious need to improve their efficiency. NK cells persist in vivo, but the heightened expression levels of activation markers and activating receptors are lost within days of transfer. Also, the transferred NK cells delay the disease with only a few days, and improved protocols for pre-activation and for maintaining heightened activity of NK cells in vivo are needed. The latter has been tackled by infusion of low-dose IL-2, 32 but this may be a futile strategy for T-ALL. Instead IL-15 could represent a more optimal strategy. Obtaining sufficient numbers of expanded pre-activated autologous NK cells from cancer patients in a clinical setting is at present technically challenging. These NK cells are also potentially functionally impaired, and also face inhibition through self MHC class I expressed by leukemic blasts, although we clearly demonstrate that this latter problem is partly overcome by cytokine pre-activation of NK cells. Alternatively, cytokine pre-activated allogeneic haploidentical NK cells could represent a more feasible approach, as recently demonstrated in a clinical trial of relapsed/refractory AML by Fehniger and colleagues. 32 The use of haploidentical NK cells is safe and more feasible, and not associated with any detrimental graft-versus-host reactions. 7 In summary, we show that NK cells are functionally suppressed in T-ALL patients at diagnosis and in rats suffering from RL. We show in the rat model that the suppressed NK 
Materials
Patients and healthy controls
PBMCs were collected at diagnosis and before therapy initiation from 19 patients admitted between 1982 to 1997 at the Royal Victoria Infirmary in Newcastle, UK, and from 3 patients rat Ly49s3/i3/s4/i4 (DAR13), rat NKp46 (Wen23), rat NKR-P1B PVG (STOK27), rat CD2 (OX34), rat CD48 (OX45), rat MHC-1 (OX18), and rat CD45.2 (His41) were generated from hybridomas and conjugated according to standard protocols. Anti-rat NKG2D antibody was a kind gift from Dr. S. Krams. 54 Cells were labelled with relevant antibodies and analyzed by Fortessa, LSRII, or FACSCalibur (BD Biosciences). Frozen, human samples were thawed immediately prior to use, and dead cells were excluded from analysis using the Fixable Viability Dye eFluor780 (eBiosciences, cat.no. 65-0865-14). Lymphocytes (singlets) were gated by forward and side scatter. Rat NK cells were gated as NKR-P1A + CD3 -, and human NK cells as CD56 + CD3 -CD14 -CD19 -. Data were analysed using FlowJo software (TreeStar, Ashland, OR). 
Cells and cell cultures
Enrichment of NK cells and cytokine pre-activation
Rat NK cells were enriched from mononuclear spleen cells by incubation in nylon wool (PolySciences, cat.no. 18369-50) at 37°C for 45 min, followed by negative selection using a mixture of antibodies towards T cells (R73 and OX19), B cells (OX12 and OX33), monocytes (ED1), and macrophages/granulocytes (OX41), and Pan mouse IgG Dynabeads (Thermo Fisher Scientific, cat.no. 11041). Cytokine pre-activated NK cells were generated by overnight cultures of enriched NK cells with 10 ng/ml IL-12 (Sigma-Aldrich, cat.no. SRP4163), 10 ng/ml IL-15 (PeproTech, cat.no. 400-24), and 50 ng/ml IL-18 (R&D Systems, cat.no. 521-RL-025)).
Roser leukemia (RL) model
The radiation induced T cell lymphoblastic leukemia RL (originating from the PVG strain; CD45.1 allotype) was a gift from Dr. Roser, Cambridge, UK. Leukemia was induced by i.v. injection of 4x10 4 RL into the tail vein of rats from the PVG.7B strain (CD45.2 allotype).
Propagation of RL injected i.v. occurs primarily in the spleen, but are detected in high numbers in blood and bone marrow during late stages of the disease 39 . The disease was monitored by blood samplings from the tail vein, and RL identified as CD45.1 -CD3 + cells by flow cytometry. The endpoint was set to 30 % RL amongst PBMCs. Blood, spleen, and bone marrow was collected for analysis at sacrifice. For in vivo targeting by NK cells, rats were sub-lethally irradiated at 4 Gy from an X-ray source (RS320, Xstrahl Life Sciences, UK), followed by injection of RL 24 hrs later. IL-12, IL-15, and IL-18 pre-activated NK cells were washed 4 times in PBS, and 4-6x10 6 cells were injected per rat at days 3, 6, and 9. Control rats were irradiated and injected with RL only. All rats within an experimental series were terminated when blasts reached >30 % of PBMC in control rats.
CD107a degranulation and 51 Cr release assays
Degranulation by rat NK cells was measured using a hamster anti-rat CD107a antibody generated in our laboratory as previously described. With this antibody 10-15 % degranulation is measured against potent target cells. 55 Degranulation by human NK cells were measured by incubating 100 µl PBMC (2x10 6 cells/ml) with 100 µl K562 target cells (2x10 6 cells/ml) in the presence of anti-human CD107a-BV510 (BD Biosciences, cat.no. 563078) for 6 hrs, with Brefeldin A (Sigma-Aldrich, B7651) added at 5 µg/ml for the last 5 hrs. NK cell cytotoxicity was measured with a standard 51 Cr release assay, using enriched NK cells as effector cells and 51 Cr-labelled YAC-1, YB2/0, or RL as target cells as previously described. 56 For blocking experiments, blocking antibodies were added at 5 µg/ml. Results are presented as mean values from triplicates for each E:T cell ratio.
Analysis of intracellular IFN-γ and Ki67 expression
Intracellular IFN-γ expression in human NK cells was measured after 6 hrs of culture of PBMC in the presence of K562 target cells as described above for the degranulation assay. Table 1 . All samples were normalized to Cd45 expression. Expression levels are reported as log transformation of 2^-ΔCt (LOG2RQ).
Conjugate assay
Enriched splenic NK cells were labelled with 0.5 µM CFSE (Thermo Fisher Scientific, cat.no. C1157) at 3×10 6 cells/ml in PBS and 2% FBS for 10 min at 37°C, and anti-NKR-P1A Alexa647. Target cells (YAC-1 or RL) were stained with seminaphtharhodafluor (SNARF-1) (Thermo Fisher Scientific, cat.no. C1270) according to the manufacturer's protocol. 100 µl enriched NK cells (3×10 5 cells) were mixed with 100 µl target cells (3×10 5 cells) with an effector to target ratio 1:1, spun for 30 s at 300 g, and incubated at 37°C for 2, 10, 60 or 120 min. Reactions were stopped by addition of 2% paraformaldehyde. As negative control target and effector cells were mixed after fixation. Conjugate formation was analyzed by flow cytometry, and percentage of NKR-P1A + NK cells in conjugates with target cells calculated.
ELISA
Serum samples were obtained at sacrifice and stored at -80˚C until use. Supernatants were obtained after overnight co-culture of RL with enriched splenic NK cells at different RL:NK cell ratios, and stored at -20˚C until use. Concentrations of TGF-β in serum and cell culture supernatants were measured in duplicates using the Quantikine ELISA kit for Mouse/Rat/Porcine/Canine TGF-β1 (R&D Systems, cat.no. MB100B) following the manufacturer's instructions. Samples were activated for 10 minutes with 1N HCl and neutralized with 1.2N NaOH/0.5M HEPES. Serum samples were diluted 1:60 prior to assay.
Absorbance was read at 450 nm, and concentrations interpolated from a standard curve.
Statistical analysis
Graphics and statistical analysis were performed with the GraphPad Prism software. Data are presented as the mean ± standard error of the mean (SEM). Statistical significance was calculated using the non-parametrical Mann-Whitney U test or the Kruskal-Wallis test. P values less than 0.05 were considered statistically significant. 
Figure legends
